Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
|Podcasts|June 12, 2023
The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis
Author(s)Emma Andrus, Assistant Editor
In this episode, Jonathan Silverberg, MD, PhD, MPH, discusses of the effects of environmental pollutants on atopic dermatitis, including flares, severity, and recommendations for avoiding these pollutants when possible.
Advertisement
Advertisement
Related to this article
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
2
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
3
ATI-052 Shows Rapid Improvements in Atopic Dermatitis
4
FDA Revises TB Evaluation Guidance for SKYRIZI
5